Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs)

References

• Patel SH, Edwards MJ, Ahmad SA. Intracellular ion channels in pancreas cancer. Cell Physiol Biochem. 2019;53:44–51.
   PubMedGoogle Scholar
• McGuire S. World cancer report 2014. Geneva, Switzerland: world Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Advances in Nutrition (Bethesda, Md). 2016;7:418–419.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD. Cancer statistics. CA Cancer J Clin. 2019;69(1):7–34. doi: 10.3322/caac.21551.
   Google Scholar
• Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017 May;66(5):1103-1110
   Google Scholar
• Bosetti C, Rosato V, Li D, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the international pancreatic cancer case-control consortium. Ann Oncol. 2014;25:2065–2072.
   PubMed Web of Science ®Google Scholar
• Strobel O. Optimizing the outcomes of pancreatic cancer surgery. Neoptolemos J. 2019;16:11–26.
   Google Scholar
• Yamashita Y, Kitano M. Value of endoscopy for early diagnosis of pancreatic carcinoma. Dig Endosc. Dig Endosc. 2020 Jan;32(1):27-36 .doi:10.1111/den.13467.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics.CA Cancer J Clin. 2018 Jan;68(1):7-30.
   Google Scholar
• Luo G, Fan Z, Gong Y, et al. Characteristics and outcomes of pancreatic cancer by histological subtypes. Pancreas. 2019;48:817–822.
   PubMed Web of Science ®Google Scholar
• Yako YY, Kruger D, Smith M, et al. Cytokines as biomarkers of pancreatic ductal adenocarcinoma: a systematic review. PloS One. 2016;11:e0154016.
   PubMed Web of Science ®Google Scholar
• Lu C, Paschall AV, Shi H, et al. The MLL1-H3K4me3 Axis-Mediated PD-L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017; (109):djw283. DOI:10.1093/jnci/djw283.
   Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Pihlak R, Weaver JMJ, Valle JW, et al. Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy. Cancers (Basel). 2018 Jan 12;10(1):17. doi: 10.3390/cancers10010017
   PubMed Web of Science ®Google Scholar
• Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11:733–739.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu P, Tong Y, et al. An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma. Oncotargets and Therapy. 2019;12:7005–7014.
   PubMed Web of Science ®Google Scholar
• Heinäniemi M, Nykter M, Kramer R, et al. Gene-pair expression signatures reveal lineage control. Nat Methods. 2013;10:577–583.
   PubMed Web of Science ®Google Scholar
• Li B, Cui Y, Diehn M, et al. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol. 2017;3:1529–1537.
   PubMed Web of Science ®Google Scholar
• Popovici V, Budinska E, Tejpar S, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 2012;30:1288–1295.
   PubMed Web of Science ®Google Scholar
• Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. 2019;20(3):676.
   PubMed Web of Science ®Google Scholar
• Liu X, Wu S, Yang Y, et al. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacothe. 2017;95:55–61.
   PubMed Web of Science ®Google Scholar
• Cole C, Lau S, Backen A, et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther. 2010;10:495–504.
   PubMed Web of Science ®Google Scholar
• Motoyama K, Tanaka F, Kosaka Y, et al. Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol. 2008;15:1530–1537.
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer. 2019;121:5–14.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8–18.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024.
   PubMed Web of Science ®Google Scholar
• Qian ZR, Rubinson DA, Nowak JA, et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 2018;4:e173420.
   PubMed Web of Science ®Google Scholar
• Yachida S, White CM, Naito Y, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res off J Am Assoc Cancer Res. 2012;18:6339–6347.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.
   PubMed Web of Science ®Google Scholar
• Eddy JA, Sung J, Geman D, et al. Relative expression analysis for molecular cancer diagnosis and prognosis. Technol Cancer Res Treat. 2010;9:149–159.
   PubMed Web of Science ®Google Scholar
• Lee NH, Nikfarjam M, He H. Functions of the CXC ligand family in the pancreatic tumor microenvironment. Pancreatology. 2018;18:705–716.
   PubMed Web of Science ®Google Scholar
• Lux A, Kahlert C, Grützmann R, et al. c-Met and PD-L1 on circulating exosomes as diagnostic and prognostic markers for pancreatic cancer.  2019;20(13):3305.
   Google Scholar
• Xu M, Li L, Liu Z, et al. ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance. Cancer Lett. 2013;333:152–158.
   PubMed Web of Science ®Google Scholar
• Sakai T, Mashima H, Yamada Y, et al. The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer. Pancreas. 2014;43:909–916.
   PubMed Web of Science ®Google Scholar
• Feng L, Qi Q, Wang P, et al. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res. 2018;46:5228–5236.
   PubMed Web of Science ®Google Scholar
• Wartenberg M, Cibin S, Zlobec I, et al. Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance. Clin Cancer Res.  2018;24:4444–4454.
   Google Scholar
• Wu J, Zhao Y, Zhang J, et al. Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology. 2019;8:1596715.
   PubMed Web of Science ®Google Scholar
• Sun XY, Yu SZ, Zhang HP, et al. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma. Cancer Med. 2020;9:2868–2878.
   PubMed Web of Science ®Google Scholar